DE69621021D1 - Inhibitoren der plättchenaggregation - Google Patents

Inhibitoren der plättchenaggregation

Info

Publication number
DE69621021D1
DE69621021D1 DE69621021T DE69621021T DE69621021D1 DE 69621021 D1 DE69621021 D1 DE 69621021D1 DE 69621021 T DE69621021 T DE 69621021T DE 69621021 T DE69621021 T DE 69621021T DE 69621021 D1 DE69621021 D1 DE 69621021D1
Authority
DE
Germany
Prior art keywords
inhibitors
plate aggregation
aggregation
plate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69621021T
Other languages
English (en)
Other versions
DE69621021T2 (de
Inventor
David Cox
Anthony Ingall
Paul Willis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9514074.5A external-priority patent/GB9514074D0/en
Priority claimed from GBGB9520311.3A external-priority patent/GB9520311D0/en
Priority claimed from GBGB9522837.5A external-priority patent/GB9522837D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE69621021D1 publication Critical patent/DE69621021D1/de
Publication of DE69621021T2 publication Critical patent/DE69621021T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69621021T 1995-07-11 1996-07-04 Inhibitoren der plättchenaggregation Expired - Fee Related DE69621021T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9514074.5A GB9514074D0 (en) 1995-07-11 1995-07-11 Compounds
GBGB9520311.3A GB9520311D0 (en) 1995-10-05 1995-10-05 Compounds
GBGB9522837.5A GB9522837D0 (en) 1995-11-08 1995-11-08 Compounds
PCT/SE1996/000911 WO1997003084A1 (en) 1995-07-11 1996-07-04 New inhibitors of platelet aggregation

Publications (2)

Publication Number Publication Date
DE69621021D1 true DE69621021D1 (de) 2002-06-06
DE69621021T2 DE69621021T2 (de) 2002-10-31

Family

ID=27267806

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69621021T Expired - Fee Related DE69621021T2 (de) 1995-07-11 1996-07-04 Inhibitoren der plättchenaggregation

Country Status (25)

Country Link
US (1) US5747496A (de)
EP (1) EP0840740B1 (de)
JP (1) JP4084415B2 (de)
KR (1) KR100444123B1 (de)
CN (1) CN1069321C (de)
AR (1) AR003453A1 (de)
AT (1) ATE217010T1 (de)
AU (1) AU699034B2 (de)
BR (1) BR9609467A (de)
CA (1) CA2226758A1 (de)
CZ (1) CZ297200B6 (de)
DE (1) DE69621021T2 (de)
EE (1) EE03616B1 (de)
HU (1) HU221880B1 (de)
IL (1) IL122814A (de)
IS (1) IS1790B (de)
MY (1) MY116542A (de)
NO (1) NO310624B1 (de)
NZ (1) NZ312258A (de)
PL (1) PL182680B1 (de)
SA (1) SA96170272B1 (de)
SK (1) SK283206B6 (de)
TR (1) TR199800019T1 (de)
TW (1) TW427996B (de)
WO (1) WO1997003084A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028300A1 (en) * 1996-12-20 1998-07-02 Astra Pharmaceuticals Ltd. Triazolo[4,5-d]pyrimidinyl derivatives and their use as medicaments
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
SE9702772D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702774D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702773D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
DE69905451T2 (de) * 1998-02-17 2003-11-20 Astrazeneca Uk Ltd Neue triazolo(4,5d) pyrimidinverbindungen
SE9802574D0 (sv) * 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6897201B2 (en) * 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US20020169730A1 (en) * 2001-08-29 2002-11-14 Emmanuel Lazaridis Methods for classifying objects and identifying latent classes
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
WO2004092172A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
WO2004092170A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
EP1615931A1 (de) * 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazine und verfahren zu deren herstellung und anwendung
EP1618108A2 (de) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Als a2a-adenosinrezeptorantagonisten geeignete triazolo[1,5-a]pyrimidine und pyrazolo[1,5-a]pyrimidine
US7834014B2 (en) * 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7368438B2 (en) * 2003-10-21 2008-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for inhibiting platelet aggregation
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
JP2007509180A (ja) * 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
US7566722B2 (en) * 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
AR072938A1 (es) * 2008-08-20 2010-09-29 Southern Res Inst Derivados de piridina y pirimidina azosustituidos y su uso en el tratamiento de infecciones virales
CA2788072A1 (en) 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
BR112014013085A2 (pt) 2011-11-30 2017-06-13 Actavis Group Ptc Ehf forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
JP6145574B2 (ja) * 2013-06-27 2017-06-14 スーヂョウ ミラクファーマ テクノロジ カンパニー リミテッドＳｕｚｈｏｕ Ｍｉｒａｃｐｈａｒｍａ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． チカグレロールの調製方法
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
CN112915063B (zh) * 2021-01-25 2022-12-20 刘红枚 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
CN112876485A (zh) * 2021-01-25 2021-06-01 郭丽伟 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
RU2770405C1 (ru) * 2021-07-05 2022-04-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные триазола, проявляющие антиагрегационную активность

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
JP2619710B2 (ja) * 1989-02-27 1997-06-11 日本製紙 株式会社 ２′，３′−ジデオキシプリンヌクレオシド類の製造方法
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
WO1994018215A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives

Also Published As

Publication number Publication date
CA2226758A1 (en) 1997-01-30
US5747496A (en) 1998-05-05
KR19990028885A (ko) 1999-04-15
CN1195353A (zh) 1998-10-07
EE03616B1 (et) 2002-02-15
EP0840740B1 (de) 2002-05-02
ATE217010T1 (de) 2002-05-15
HUP9802448A3 (en) 2000-03-28
AR003453A1 (es) 1998-08-05
SK283206B6 (sk) 2003-03-04
HU221880B1 (hu) 2003-02-28
NO310624B1 (no) 2001-07-30
CZ297200B6 (cs) 2006-09-13
KR100444123B1 (ko) 2004-10-14
WO1997003084A1 (en) 1997-01-30
DE69621021T2 (de) 2002-10-31
MY116542A (en) 2004-02-28
NZ312258A (en) 1999-08-30
CZ2598A3 (cs) 1998-08-12
AU699034B2 (en) 1998-11-19
NO980080D0 (no) 1998-01-08
NO980080L (no) 1998-03-06
IS1790B (is) 2001-11-28
IL122814A0 (en) 1998-08-16
IL122814A (en) 2001-04-30
JP4084415B2 (ja) 2008-04-30
TR199800019T1 (xx) 1998-05-21
JPH11508914A (ja) 1999-08-03
SA96170272B1 (ar) 2006-06-04
AU6375196A (en) 1997-02-10
HUP9802448A2 (hu) 1999-05-28
SK2398A3 (en) 1999-01-11
TW427996B (en) 2001-04-01
MX9800308A (es) 1998-09-30
EP0840740A1 (de) 1998-05-13
IS4647A (is) 1998-01-08
CN1069321C (zh) 2001-08-08
PL182680B1 (pl) 2002-02-28
BR9609467A (pt) 1999-03-02
PL324396A1 (en) 1998-05-25
EE9800026A (et) 1998-08-17

Similar Documents

Publication Publication Date Title
DE69621021D1 (de) Inhibitoren der plättchenaggregation
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
IS4771A (is) Interlevkín-1ß umbreytiensím tálmar
NO942064D0 (no) yminhibitorer
FI972160A (fi) Matriisimetalloproteaasi-inhibiittorit
DE69324988T2 (de) Überprüfung des Sprechers
DE69319209T2 (de) Plattenanordnung
ATE222240T1 (de) Hiv - protease inhibitoren
NO932620D0 (no) Amindiol-proteaseinhibitorer
DE69526196T2 (de) Befestigungsteller
DE68904083T2 (de) Hmg-coa-reduktaseinhibitoren.
DE69513932T2 (de) Verankerungsplatte
DE68901091D1 (de) Hmg-coa-reduktaseinhibitoren.
DE69329894D1 (de) Arylamidderivate
DE69524752T2 (de) Schaltungsanordnung zum Vorkommen von Streifen
NO980643D0 (no) Propylendopeptidase inhibitorer
ATA87395A (de) Plattenbefestigung
DE69523450T2 (de) Inhibitor
KR960004711U (ko) 글로브 박스의 유격흡수판
BR9610514A (pt) Inibidores cicloantihelmínticos
ITRM930479A1 (it) Piastra antiballone
KR950012224U (ko) 냉장고후판의 간격유지구
KR970006550U (ko) 모자이크화된 온돌용 판
KR940006795U (ko) 관리기의 측방장착식 적치대
NO921431D0 (no) Platejekk

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee